Comparative Pharmacology
Head-to-head clinical analysis: IOFLUPANE I 123 versus SODIUM CHROMATE CR 51.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOFLUPANE I 123 versus SODIUM CHROMATE CR 51.
IOFLUPANE I-123 vs SODIUM CHROMATE CR 51
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ioflupane I-123 is a radiopharmaceutical that binds with high affinity to the dopamine transporter (DAT) in the striatum. It allows visualization of presynaptic dopaminergic neurons via single-photon emission computed tomography (SPECT) imaging.
Radiolabeled sodium chromate (51Cr) binds to red blood cells, tagging them for survival studies. 51Cr emits gamma radiation, allowing detection and quantification of RBC mass and survival via scintillation counting or imaging.
Intravenous: 148-185 MBq (4-5 mCi) administered as a single IV bolus injection over 20-30 seconds, followed by saline flush.
Intravenous injection, 5-30 microcuries (0.185-1.11 MBq) as a single dose.
None Documented
None Documented
Clinical Note
moderateIoflupane I-123 + Methylphenidate
"Ioflupane I-123 may decrease effectiveness of Methylphenidate as a diagnostic agent."
Clinical Note
moderateIoflupane I-123 + Venlafaxine
"Ioflupane I-123 may decrease effectiveness of Venlafaxine as a diagnostic agent."
Clinical Note
moderateIoflupane I-123 + Nefazodone
"Ioflupane I-123 may decrease effectiveness of Nefazodone as a diagnostic agent."
Clinical Note
moderateIoflupane I-123 + Fluvoxamine
Terminal elimination half-life of ioflupane I-123 is approximately 25-30 hours. This prolonged half-life allows for imaging up to 6-8 hours post-injection with sustained target-to-background ratio, but requires consideration for radiation safety.
The biological half-life is approximately 27–30 days. Clinically, gradual clearance from blood and tissues occurs over weeks to months.
Primarily renal; about 60% of administered radioactivity excreted in urine within 24 hours, with 38% as unchanged ioflupane and 22% as metabolites. Fecal excretion accounts for approximately 14% over 48 hours. Additional elimination via biliary route is minimal.
Primarily renal. Approximately 90% of absorbed dose is excreted in urine within 48 hours. Fecal excretion accounts for less than 5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical
"Ioflupane I-123 may decrease effectiveness of Fluvoxamine as a diagnostic agent."